Vanda Pharmaceuticals Inc
VNDAHealthcare|Biotechnology|USA
$6.24
-0.14 (-2.19%)
DCF (FCF)
$3.02
Tangible Book
$2.76
Earnings Power
$1.56
Upcoming Data Readouts (13)
Sep 2026
Est. completion
P2Onychomycosis of Toenail
Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe Onychomycosis
NCT07065773n=50
Sep 2026
Est. completion
P2Dry Eye
An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye
NCT07179055n=160
Oct 2026
Est. completion
P2Hypertension
Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension
NCT07090161n=240
Dec 2026
Est. completion
P3Nausea and Vomiting
A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use
NCT07446439n=280
Dec 2026
Est. completion
P3Social Anxiety Disorder (SAD)
Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder
NCT07221578n=500
Sep 2027
Est. completion
P3Motion Sickness
Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness
NCT06138613n=705
Nov 2027
Est. completion
Nov 2027
Est. completion
P3Insomnia Disorder
Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia
NCT06953869n=420
Dec 2027
Est. completion
P1Relapsed or Refractory Hematologic Malignancies
Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies
NCT03838926n=42
Mar 2028
Est. completion
P3Major Depressive Disorder (MDD)
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
NCT06830044n=500
Aug 2028
Est. completion
P3Moderate-to-severe Chronic Plaque Psoriasis
Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis
NCT07362017n=300
Apr 2030
Est. completion
Sleep-wake Disorder in Blind Individuals
Patient Registry of Blind Subjects With Sleep-related Problems
NCT01195558n=10,000
Dec 2030
Est. completion
Sleep Disturbances in Smith-Magenis Syndrome
Development of Clinical Database of Individuals With Smith-Magenis Syndrome and Sleep Disturbances
NCT03154697n=1,000
Awaiting Results (1)
Trials past primary completion date but still active — data readout may be imminent.
Mar 2026
P1P2
Treatment of Charcot-Marie-Tooth Disease, Axonal, Type 2S (CMT2S) in an Individual Patient
NCT07223632